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Abstract
Background: Microalbuminuria is a known risk factor for cardiovascular morbidity and 
mortality suggesting that it should be a marker of endothelial dysfunction. Albumin to creati-
nine ratio (ACR) is an available and rapid test for microalbuminuria determination, with  
a high correlation with the 24-h urine collection method. There is no prospective study that 
evaluates the prognostic value of ACR in patients with non ST-segment elevation acute coro-
nary syndromes (NSTE-ACS). The purpose of our study was to detect the long-term prognostic 
value of ACR in patients with NSTE-ACS.
Methods: Albumin to creatinine ratio was estimated in 700 patients with NSTE-ACS at 
admission. Median follow-up time was 18 months. The best cutoff point of ACR for death or 
acute myocardial infarction was 20 mg/g. Twenty-two percent of patients had elevated ACR.
Results: By multivariable Cox regression analysis, ACR was an independent predictor of the 
clinical endpoint: odds ratio 5.8 (95% confidence interval [CI] 2–16), log-rank 2 p < 0.0001 
in a model including age > 65 years, female gender, diabetes mellitus, creatinine clearance, 
glucose levels at admission, elevated cardiac markers (troponin T/CK-MB) and ST segment 
depression. The addition of ACR significantly improved GRACE score C-statistics from 0.69 
(95% CI 0.59–0.83) to 0.77 (95% CI 0.65–0.88), SE 0.04, 2 p = 0.03, with a good calibration 
with both models.
Conclusions: Albumin to creatinine ratio is an independent and accessible predictor of 
long-term adverse outcomes in NSTE-ACS, providing additional value for risk stratification. 
(Cardiol J 2016; 23, 3: 236–241)
Key words: microalbuminuria, acute coronary syndromes, prognosis
Introduction
Cardiovascular disease is currently the main 
cause of death in the Western world. In 2008, ac-
cording to the World Health Organization (WHO), 
7,500,000 people died of ischemic heart disease, 
representing 12.8% of total deaths worldwide [1]. 
Non-ST-segment elevation acute coronary syn-
drome (NSTE-ACS) represents a prevalent and 
heterogeneous population with a broad spectrum 
of outcomes [2].
Microalbuminuria (MA), defined as urinary albu-
min excretion elevation between 30 and 300 mg/day 
was initially used as a kidney damage marker 
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in diabetic patients [3–5] but subsequently it 
was shown to be a good marker of risk of total 
and cardiovascular mortality among diabetic and 
hypertensive patients, as well as in the overall 
population [6–8]. MA also proved to be a marker 
of short- and long-term follow-up adverse events 
in patients with acute myocardial infarction (AMI) 
[9–14]. Finally, there is a broad evidence about the 
close correlation between the albumin to creatinine 
ratio (ACR) obtained from a spot urine sample with 
the MA collected in a 24 h period [15].
There is no information on the prognostic 
value of ACR in a NSTE-ACS population.
Methods
This study was conducted to test prospectively 
the hypothesis that ACR is independently associ-
ated with long-term adverse outcomes in NSTE-
-ACS patients. We excluded those with history of 
renal failure defined as a glomerular filtration rate 
below 60 mL/min/1.73 m2 by the use of Modifica-
tion of Diet in Renal Disease equation, history of 
macroalbuminuria, or previous diuretic treatment 
≥ 24 h before admission, urinary and respiratory tract 
infections. The primary endpoint analyzed was the 
occurrence of death and/or AMI at 24-month fol-
low-up. AMI is defined by WHO criteria (ischemic 
symptoms, changes in ST segment, development 
of new Q waves, typical creatinine phosphokinase 
curve × 3 post angioplasty, and × 5 post coronary 
artery bypass graft surgery [CABG]). All patients 
gave their written informed consent before their 
inclusion in the study. The protocol was approved 
by our local Review Board Committee.
GRACE score 2.0 was calculated for all the 
patients of the study [2].
Follow-up assessments were performed by 
means of questionnaires, examinations, telephone 
interviews, review of medical records, and reports 
from personal physicians.
The study was approved by our institutional 
Review Board and conducted in compliance with 
the Declaration of Helsinki, Good Clinical Practice 
guidelines, and local regulatory requirements.
Biochemical considerations
A urine sample was taken during the first 24 h 
following admission (preferably in the morning 
hours). The samples were centrifuged at 3,000 rpm, 
storing them at –20°C for later analysis. The 
principle of the ACR measurement test is immuno-
turbidimetry. This method is based on the reaction 
of human albumin antibodies with the antigen. The 
complexes are then measured after its agglutina-
tion. The COBAS 6000 analyzer (ROCHE) was 
used for sample processing. The analytical detec-
tion limits of the assay were 3 mg/g and 400 mg/g. 
The test variation coefficient was 3.8%.
Statistical aspects
Analysis of distribution of continuous variables 
was performed using the Kolmogorov-Smirnov 
test and analysis of kurtosis-skewness. Data were 
expressed as mean and standard deviation, or as 
its median and its 25th and 75th interquartile and 
a comparison was made using the Student’s t-test 
or the Mann-Whitney-Wilcoxon test for independ-
ent groups, according to its parametric or non-
parametric distribution, respectively.
Discrete variables were expressed as percent-
ages. We used the c2 test for comparison purposes. 
The cross product ratio will be expressed as odds ra-
tio (OR) with a confidence interval of 95% (95% CI). 
C-statistics was used to detect the best cutoff value 
of the ACR in relation to the primary endpoint 
and to compare discrimination capacity between 
the GRACE score alone and with the addition of 
the ACR.
Actuarial survival curves were constructed by 
the Kaplan-Meier method based on the study end-
point for each dichotomous variable. The log-rank 
test was used for comparisons. Cox proportional 
regression models were used to identify variables 
that were independently associated with the end-
point. Variables with a value of p < 0.1 in the 
bivariate analysis, those (mostly historical) which 
had caused confusion in the relationship between 
the ACR and the endpoint being were included 
in the model. Model calibration was assessed 
through the Hosmer-Lemeshow test. For the cor-
relation between continuous variables the Pearson 
P coefficient was used. All statistical comparisons 
were 2-tailed, considering significant a probability 
(2 p) of less than 5%. For statistical analysis the 
IBM Statistics SPSS version 19 software and the 
MedCalc software version 11.6.1. (Mariakerke, 
Belgium) were used for construction and compari-
son of C-statistics. To test the additional predictive 
value of ACR we compared C-statistics for GRACE 
score alone and the GRACE score plus the ACR 
information.
Results
Seven hundred consecutive patients were 
analyzed with a final diagnosis of NSTE-ACS. 
Twenty-six patients were excluded due to history 
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of renal failure and next 27 for prior treatment with 
loop-diuretics.
The average age was 63 ± 12 years old. Thirty 
percent were women, 65% had hypertension, and 
one fifth were diabetic. Half of the studied popula-
tion had a history of dyslipidemia and 43% were 
active smokers, 19% had a history of ACS, 5.3% had 
undergone CABG and 14.2% coronary angioplasty. 
Table 1 describes the demographic and clinical 
baseline characteristics of the population.
The medium ACR was 6 mg/g (interquartile 
range 25–75: 0–20 mg/g). For the lineal logistic 
regression, both the diabetes and previous stroke/ 
/transient ischemic attack were the only variables 
independently associated with ACR as continuous 
variables: p = 0.02 and p = 0.004, respectively. 
Thirty percent of the studied population had no 
history of diabetes or hypertension.
Patients with elevated ACR were significantly 
associated with history of hypertension and dia-
betes, and with peak concentrations of troponin T, 
total creatinine phosphokinase, creatinine kinase 
(CK)-MB, plasma creatinine and plasma glucose.
On the other hand, ACR had a negative cor-
relation with creatinine clearance values.
Median follow-up time was 18 (12–24) months. 
Ninety-five percent of the appointments were per-
sonal contacts as hospital controls or in a private 
office.
Based on the C-statistics analysis, the best 
ACR cutoff value associated with the clinical 
endpoint (death/AMI) was 20 mg/g. Twenty-two 
Table 1. Baseline demographics and clinical characteristics.
Variable Total  
(n = 700)
ACR £ 20 mg/g  
(n = 574)
ACR > 20 mg/g  
(n = 126)
P
Age [years] 63 (56–73) 61 (5–71) 68 (57–76) 0.01
Women 245 (35%) 212 (37%) 34 (27%) 0.08
Diabetes 133 (19%) 92 (16%) 35 (28%) 0.01
Hypertension 455 (65%) 356 (62%) 94 (75%) 0.03
Dyslipidemia 385 (55%) 310 (54%) 72 (57%) 0.6
Active smoking 301 (43%) 241 (42%) 57 (45%) 0.5
Previous AMI: 133 (19%) 126 (22%) 23 (18%) 0.9
CABG 37 (5.3%) 32 (5.6%) 9 (7.1%) 0.9
PCI 99 (14.2%) 86 (15%) 13 (10%) 0.09
Angina 46 (6.6%) 37 (6.5%) 15 (11.8%) 0.9
Stroke 21 (3%) 14 (2.5%) 9 (7.1%) 0.04
COPD 22 (3.2%) 18 (3.1%) 7 (5.9%) 0.1
ACE-I/ARB 287 (41%) 224 (39%) 62 (49%) 0.07
Beta-blockers 245 (35%) 212 (37%) 53 (42%) 0.4
Aspirin 245 (35%) 103 (18%) 31 (25%) 0.2
ST depression at admission 98 (14%) 86 (15%) 25 (20%) 0.2
Severe LV dysfunction 10 (1.5%) 7 (1.3%) 3 (2.4%) 0.6
Cardiogenic shock 28 (4%) 11 (2%) 13 (10%) 0.001
Peak troponin T [ng/dL]: 0.01 (0–0.21) 0.001 (0–0.15) 0.1 (0–0.9) 0.0001
CK [UI/L] 121 (73–258) 115 (70–211) 188 (88–560) 0.02
CK-MB [UI/L] 16 (12–34) 15 (11–28) 18 (13–69) 0.006
Serum creatinine [mg/dL] 0.8 (0.9–1.1) 0.9 (0.8–1) 1 (0.8–1.2) 0.0001
Creatinine clearance [mL/h] 66 (86–107) 90 (70–110) 70 (50–90) 0.001
Admission glycaemia [mg/dL] 110 (98–133) 108 (97–123) 121 (101–166) 0.0001
Systolic blood pressure [mm Hg] 140 (120–150) 140 (120–150) 140 (120–160) 0.1
Heart rate [bpm] 70 (63–80) 72 (64–80) 75 (63–85) 0.2
ACE-I/ARB — angiotensin converting enzyme inhibitors/angiotensin II receptor blockers; AMI — acute myocardial infarction; ACR — albumin 
to creatine ratio; CABG — coronary artery bypass graft; CK — creatinine phosphokinase; CK-MB — creatinine kinase MB; COPD — chronic 
obstructive pulmonary disease; LV — left ventricular; PCI — percutaneous coronary intervention
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percent of the population presented higher values 
than this cutoff value and 1.2% corresponded to 
values that were compatible with macroalbuminu-
ria (ACR > 300 mg/g).
At follow-up, the endpoint incidence was signif-
icantly higher among those with an ACR > 20 mg/g: 
12% vs. 2.2%, 2 p = 0.0001. This association was 
detected both in patients with history of hyper-
tension (OR 6.8, 95% CI 1.2–37, p = 0.002) and 
in those without history of hypertension (OR 1.3, 
95% CI 1.1–5.4, p = 0.02), in diabetics (OR 2.3, 
95% CI 1.7–7.1, p = 0.01) and in non-diabetics 
(OR 1.5, 95% CI 1.1–7.1, p = 0.01), and patients 
with unstable angina (OR 6.8, 95% CI 1.2–37, 
p = 0.02) and in those with myocardial infarction 
(OR 1.3, 95% CI 1.2–5.4, p = 0.04).
Albumin to creatininee ratio values were 
higher in patients with events at the follow-up than 
in those with no events: 20 mg/g (0–42) vs. 5 mg/g 
(0–15), 2 p < 0.001.
Combined endpoint was achieved in 31 (4.5%) 
cases of the total population. There were 20 (3.3%) 
deaths: (17/20) 85% were cardiac deaths, 11 of 17 
(64%) due to cardiogenic shock/acute pulmonary 
edema. Endpoints were higher in those with ACR 
> 20 mg/g than those with ACR ≤ 20 mg/g: 7% vs. 
2.9%, p = 0.04.
Kaplan-Meier analysis demonstrated that pa-
tients with ACR > 20 mg/g had a higher prevalence 
of death/AMI at 24 months; log-rank test c2 19, 
2 p < 0.0001 (Fig. 1).
In the Cox multivariate regression model, 
ACR was found to be an independent predictor of 
death/AMI: OR 5.8 (95% CI 2–16), 2 p < 0.001, 
adjusted for age > 65 years, female gender, diabe-
tes mellitus, creatinine clearance, glucose levels at 
admission, elevated cardiac markers (troponin T/ 
/CK-MB) and ST segment depression (Table 2).
C-statistics of GRACE score alone was 0.69 
(95% CI 0.59–0.83). This value increased with 
the addition of the ACR value from 0.69 (95% 
CI 0.59–0.83) to 0.77 (95% CI 0.65–0.88), SE 0.04, 
2 p = 0.03.
Hosmer-Lemeshow test showed a good cali-
bration in both models: its X2 for the GRACE score 
was 1.6 (p = 0.3) and for the GRACE score with the 
addition of ACR it was 1.3 (p = 0.8), respectively, 
denoting a good concordance between observed 
and expected events in all subgroups of risk.
Discussion
To our knowledge, this is the first prospective 
study that demonstrated the independent predic-
Figure 1. A. Event-free actuarial survival curves at 6-month follow-up in patients with an albumin to creatinine ratio 
(ACR) ≤ 20 mg/g vs. those with ACR > 20 mg/g; B. Event-free survival curves plotted on a logarithmic scale.
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tive power of ACR in NSTE-ACS patients. As 
mentioned above, previous reports assessed the 
prognostic value of MA in observational studies of 
patients with diagnosis of AMI. There is just one 
experience with MA in NSTE-ACS patients but 
derived from randomized controlled study with 
a selected population [16].
We chose ACR measurement for its high cor-
relation with the 24 h urine MA method, simple 
collection and widespread availability.
As occurred in previous studies, the predictive 
cutoff value of ACR (> 20 mg/g) for cardiovascular 
endpoints was below the conventional thresholds 
for the detection of renal injury (e.g. 30 mg/g) [17, 
18], taking into account a continuous relationship 
of this marker and the outcomes.
It is important to highlight that this association 
was observed regardless of the renal function state 
and of the presence or absence of history of diabetes.
We highlight the incremental value of a robust 
stratification tool like the GRACE score with the 
addition of ACR measurement, both in patients 
with unstable angina and NSTE-ACS.
The association mechanism between MA and 
prognosis among ACS patients is unknown. To 
date, there has been some evidence regarding its 
association with the process of atherosclerosis. For 
example, the MA was related to signs of endothe-
lial dysfunction (e.g. lower vascular reactivity to 
vasodilators and increased activity of endothelial 
adhesion molecules). In the same way, MA was 
associated with increased carotid intima–media 
thickness in patients with type 1 diabetes. There is 
also evidence of its association with typical signs of 
inflammation, such as leukocytosis and an increase 
of inflammatory markers.
Finally, there are reports about its relationship 
with increased coagulation factor activity, such 
as the production of tissue factor and factor VII 
[19–28].
Therapeutic implications
In studies such as the ABCD and RENAAL, 
it has been noted that the reduction of MA in dia-
betic patients treated with angiotensin converting 
enzyme inhibitors/angiotensin II receptor blockers 
was associated with long-term reduction of cardio-
vascular events. In the future, the impact on the 
reduction of MA in patients with NSTE-ACS with 
this pharmacological agent remains an attractive 
hypothesis of a study [29, 30].
Limitations of the study
Our study has several limitations. First, it is 
a single center study, so our findings must be con-
firmed in a multicenter cohort. Second, ACR was 
measured only at admission, in order to provide 
useful information for risk stratification, but we did 
not collect serial samplings during the hospitaliza-
tion period. Finally, MA was not measured by the 
standard 24 h urine sampling in order to detect 
correlation with ACR and its association with the 
clinical events.
Conclusions
Microalbuminuria determined as ACR, could in 
the future become an accessible and simple tool for 
risk stratification in NSTE-ACS, underlining that 
the ACR may be considered for risk stratification 
in clinical practice. This observation should be 
validated in other external populations.
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